Global Radiopharmaceuticals in Nuclear Medicine Market Size By Type (Diagnostic Radiopharmaceuticals, Therapy Radiopharmaceuticals), By Application (Diagnostic Application, Therapeutic Application), B...

The Global Radiopharmaceuticals in Nuclear Medicine Market was valued at USD 6.1 billion in 2023 and is projected to reach USD 12.3 billion by 2031, expanding at a CAGR of 9.1% over the forecast period (2023–2031). The rising prevalence of cancer and cardiovascular disorders, advancements in imaging technologies, and the growing demand for targeted diagnostic and therapeutic procedures are key factors propelling the market. Radiopharmaceuticals are instrumental in both diagnosis and treatment, offering precision in disease localization and real-time therapeutic monitoring, especially in oncology and cardiology.

Drivers:

1. Increasing Prevalence of Cancer and Chronic Diseases:

Rising global cancer cases and the growing incidence of cardiovascular diseases are fueling demand for radiopharmaceuticals, particularly for PET and SPECT imaging.

2. Technological Advancements in Imaging Modalities:

Integration of hybrid imaging technologies such as PET/CT and PET/MRI enhances diagnostic accuracy and expands the clinical application of radiopharmaceuticals.

3. Growing Preference for Non-Invasive Diagnostics:

Radiopharmaceuticals enable non-invasive diagnosis, providing precise physiological insights with minimal patient discomfort.

Restraints:

1. Short Half-life of Isotopes:

The limited shelf life of certain radiopharmaceuticals due to rapid decay necessitates proximity to production sites, constraining global distribution.

2. High Production and Handling Costs:

Specialized infrastructure and stringent regulatory compliance increase costs, creating barriers for widespread adoption, particularly in developing economies.

Opportunity:

1. Rising Adoption of Theranostics:

The use of radiopharmaceuticals for both therapeutic and diagnostic purposes (theranostics) is expanding, particularly in oncology for personalized treatment.

2. Expanding Nuclear Medicine Infrastructure in Emerging Markets:

Countries in Asia-Pacific and Latin America are investing in nuclear medicine facilities, presenting significant market opportunities.

Market by System Type Insights:

PET Radiopharmaceuticals held the largest market share in 2023 due to their superior resolution and accuracy in diagnosing neurological, cardiac, and oncological conditions. The segment is expected to maintain its dominance, supported by growing applications in personalized medicine and increasing use of fluorodeoxyglucose (FDG).

Market by End-use Insights:

Hospitals and Diagnostic Centers emerged as the largest end-use segment in 2023, accounting for over 60% of global revenue. This dominance is due to the widespread availability of nuclear imaging equipment and the increasing adoption of radiopharmaceuticals in routine diagnostics and therapy.

Market by Regional Insights:

North America led the global market in 2023, attributed to advanced healthcare infrastructure, high research investment, and a well-established nuclear medicine ecosystem. However, Asia-Pacific is expected to register the highest growth rate during the forecast period, driven by increasing healthcare expenditure, growing awareness, and governmental support for nuclear medicine development.

Competitive Scenario:

Prominent players in the Global Radiopharmaceuticals in Nuclear Medicine Market include Cardinal Health, GE Healthcare, Siemens Healthineers, Curium, Bracco Imaging, Jubilant Radiopharma, Lantheus Medical Imaging, Advanced Accelerator Applications (a Novartis company), and NorthStar Medical Radioisotopes. These companies are actively investing in new isotope development, strategic partnerships, and regional expansions.

Key Market Developments:

2023: Curium launched a next-generation technetium-99m generator with enhanced safety and portability.

2024: Novartis’ Advanced Accelerator Applications received FDA approval for a new targeted radioligand therapy for prostate cancer.

2025: Cardinal Health partnered with a leading Asian distributor to expand its radiopharmaceutical footprint in the Asia-Pacific region.

Scope of Work – Global Radiopharmaceuticals in Nuclear Medicine Market

FAQs:

1) What is the current market size of the Global Radiopharmaceuticals in Nuclear Medicine Market?

The market size was valued at USD 6.1 billion in 2023.

2) What is the major growth driver of the Global Radiopharmaceuticals in Nuclear Medicine Market?

The primary growth driver is the rising prevalence of cancer and chronic diseases combined with advancements in diagnostic imaging technologies.

3) Which is the largest region during the forecast period in the Global Radiopharmaceuticals in Nuclear Medicine Market?

North America is the largest regional market, although Asia-Pacific is projected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Radiopharmaceuticals in Nuclear Medicine Market?

The PET Radiopharmaceuticals segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Radiopharmaceuticals in Nuclear Medicine Market?

Key players include Cardinal Health, GE Healthcare, Siemens Healthineers, Curium, Bracco Imaging, and Lantheus Medical Imaging.